Navigation Links
Paramount Stockholders Approve Acquisition of Chem Rx

NEW YORK, Oct. 22 /PRNewswire-FirstCall/ -- Paramount Acquisition Corp. (OTC Bulletin Board: PMQC, PMQCU, PMQCW) ("Paramount") announced today that its stockholders have approved the acquisition of all of the issued and outstanding stock of B.J.K. Inc., a New York corporation doing business as Chem Rx (the "Transaction"), at a special meeting held today in New York. It is expected that the Transaction will close by Friday, October 26, 2007.

Of the 11,091,153 Paramount common shares of stock that were voted at the special meeting (representing approximately 93.2% of the shares entitled to vote on the Transaction), 10,393,068, or approximately 87.3% of the total shares outstanding, voted in favor of the Transaction. A total of 697,085 shares issued in Paramount's initial public offering voted against the Transaction, of which 637,075 elected to convert their shares into a pro rata portion of the IPO trust account.

In addition to approving the Transaction, Paramount's stockholders approved certain changes to its certificate of incorporation relating to the Transaction, including changing Paramount's name to "Chem Rx Corporation" upon the closing of the Transaction. Paramount's stockholders also approved Paramount's 2007 Incentive Compensation Plan.


Founded more than 40 years ago, Chem Rx is a major, privately-owned long- term care pharmacy serving the New York City metropolitan area, as well as parts of New Jersey, upstate New York, and Pennsylvania. Chem Rx's client base includes skilled nursing facilities and a wide range of other long-term care facilities. Chem Rx provides to more than 61,000 residents prescription and non-prescription drugs, intravenous medications, durable medical equipment items and surgical supplies. Chem Rx's website address is


Paramount Acquisition Corp. is a special purpose acquisition corporation that was formed for the specific purpose of effecting a merger, capital stock exchange, asset acquisition, or other similar business combination with an operating business in the healthcare industry. Paramount raised net proceeds of approximately $53 million through its initial public offering consummated in October 2005 and exercise of the over-allotment option, and has dedicated its attention since the offering to seeking and evaluating business combination opportunities.

Paramount Acquisition Corp. is an affiliate of Paramount BioSciences, LLC, which focuses primarily on the development of promising in-licensed drug candidates. Founded in 1991 by Lindsay A. Rosenwald, M.D., Paramount BioSciences is a unique drug development and health care financial company that, with the assistance of its affiliated life sciences merchant bank, has created approximately 50 start-up companies over the past fifteen years, about half of those over the past four years alone. Since its inception, Paramount BioSciences and its affiliated companies have been involved in the clinical development of more than seventy drug candidates - several of which have reached the market - and have over forty compounds in clinical development today. Paramount BioSciences has extensive experience in all facets of the development of emerging life sciences companies and provides its portfolio companies a wide range of professional and financial support services.

Cautionary Statements

This press release contains forward-looking statements about Paramount, Chem Rx and their combined business after completion of the proposed business combination. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of Paramount's or Chem Rx's management and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward- looking statements: compliance with government regulations; changes in legislation or regulatory environments; requirements or changes adversely affecting the health care industry, including changes in Medicare reimbursement policies; fluctuations in customer demand; management of rapid growth; intensity of competition; timing, approval and market acceptance of new product introductions; general economic conditions; geopolitical events and regulatory changes, as well as other relevant risks detailed in Paramount's filings with the SEC, including its Annual Report on Form 10-KSB for the year ended December 31, 2006. The information set forth herein should be read in light of such risks. Paramount does not assume any obligation to update the information contained in this press release.


J. Jay Lobell

Chief Executive Officer & Secretary

Paramount Acquisition Corp.

(212) 554-4522

Stephanie Carrington / Elizabeth Scott

The Ruth Group

646-536- 7017 / 7014

SOURCE Paramount Acquisition Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Fusion 2007: IT threats make risk management paramount
2. UW-Madison approves new research institute
3. FDA approves GEs heart-imaging technology
4. Senate approves bill to expand stem cell funding
5. FDA approves advanced digital mammography system
6. Building commission approves Institutes for Discovery
7. Seven good reasons to approve the Institutes for Discovery
8. Genzyme acquistion of Bone Care approved, significant impact forecast
9. UW Board of Regents approves $134 million medical research facility
10. FDA approves Bone Cares Hectorol for treatment of kidney disease
11. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
Post Your Comments:
(Date:12/1/2015)... VIEW, Calif. , Dec. 1, 2015 /PRNewswire/ ... the Transformational Health program. This program addresses ways ... period of change. ... Logo - ... every aspect of healthcare, as well as the ...
(Date:12/1/2015)... Dec. 01, 2015 ... of the "2016 Europe Cell Surface ... Technologies, Competitive Strategies, Opportunities for Suppliers--France, Germany, ... offering. --> ) has ... Europe Cell Surface Markers: Country Volume and ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... its best selling system laboratory animal colony management software solution, ezColony®, is now ... in on-site IT resources., , Many organizations are moving ...
(Date:12/1/2015)... Calif. , Dec. 1, 2015 Cepheid ... of its participation at the Piper Jaffray Healthcare Conference ... this morning, the Company is reaffirming its outlook for ... for 2016, in addition to discussing longer term business ... and Chief Executive Officer.  "We continue to be the ...
Breaking Biology Technology:
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/17/2015)... -- Paris from 17 th ... Paris from 17 th until 19 th ... has invented the first combined scanner in the world which ... surface. Until now two different scanners were required: one for ... on the same surface. This innovation is an ideal ...
(Date:11/17/2015)... Nov. 17, 2015 Pressure BioSciences, Inc. (OTCQB: ... development and sale of broadly enabling, pressure cycling technology ... industry, today announced it has received gross proceeds of ... Private Placement (the "Offering"), increasing the total amount raised ... more additional closings are expected in the near future. ...
Breaking Biology News(10 mins):